Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease
The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.
Abstract
Using the Braak staging for neurofibrillary changes as an objective indicator of the progression of Alzheimer's disease, we have performed a systematic search for global gene expression changes in the prefrontal cortex during the course of Alzheimer's disease. In the prefrontal cortex, senile plaques and neurofibrillary changes start to appear around Braak stage III, allowing for the detection of changes in gene expression before, during and after the onset of Alzheimer's disease neuropathology. Two distinct patterns of tightly co-regulated groups of genes were observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (the UPDOWN clusters; containing 865 genes) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (the DOWNUP clusters; containing 983 genes). The most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of plaque pathology and neurofibrillary changes in the prefrontal cortex. We also observed an increase in intracellular beta amyloid staining from Braak stages I to III and a clear decrease in Braak stages IV to VI. These data suggest a link between specific gene expression clusters and Alzheimer's disease-associated neuropathology in the prefrontal cortex. Gene ontology over-representation and functional gene network analyses indicate an increase in synaptic activity and changes in plasticity during the very early pre-symptomatic stage of the disease. In later Braak stages, the decreased expression of these genes suggests a reduction in synaptic activity that coincides with the appearance of plaque pathology and neurofibrillary changes and the clinical diagnosis of mild cognitive impairment. The interaction of the ApoE genotype with the expression levels of the genes in the UPDOWN and DOWNUP clusters demonstrates that the accelerating role of ApoE-ε4 in the progression of Alzheimer's disease is reflected in the temporal changes in gene expression presented here. Since the UPDOWN cluster contains several genes involved in amyloid precursor protein processing and beta amyloid clearance that increase in expression in parallel with increased intracellular beta amyloid load, just before the onset of plaque pathology in the prefrontal cortex, we hypothesize that the temporally orchestrated increase in genes involved in synaptic activity represents a coping mechanism against increased soluble beta amyloid levels. As these gene expression changes occur before the appearance of Alzheimer's disease-associated neuropathology, they provide an excellent starting point for the identification of new targets for the development of therapeutic strategies aimed at the prevention of Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early transcriptomic studies utilizing microarrays revealed alterations in synaptic, immune, and metabolic pathways that appear even before clinical symptoms, underscoring the potential for pre-symptomatic intervention120,125,161.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [125]
In the citing paper
“and the decreased expression of these synaptic genes in later Braak stages, suggesting a reduction in synaptic activity that coincides with AD neuropathology and cognitive impairment 252.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [252]
In the citing paper
“Systematic search for global gene expression changes in PFC during the course of AD has found a temporally orchestrated increase of genes involved in synaptic activity during the very early pre-symptomatic stage, probably representing a coping mechanism against increased β-amyloid levels, and the decreased expression of these synaptic genes in later Braak stages, suggesting a reduction in synaptic”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [252]
In the citing paper
“Several studies have shown altered gene expression in the post‐mortem brain of cases with AD and related animal models 7, 67, 99.”
From Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome (2016) · cites this paper as [7]
Citations
Cites
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“We selected the prefrontal cortex (PFC), because it is affected relatively late in the Alzheimer’s disease process (Braak and Braak, 1991).”
BackgroundMethodTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“, 2002), and in several transgenic mouse models for Alzheimer’s disease (Oakley et al., 2006; Oddo et al., 2006).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 2×
“In addition to ApoE, variations in CLU, PICALM and CR1 have recently been associated with sporadic Alzheimer’s disease (Harold et al., 2009; Lambert et al., 2009).”
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“Alzheimer’s disease disease progression can be monitored by the presence of tangle-bearing neurons in well-defined brain areas, and is classified into 6 Braak stages (Braak I-VI) (Braak and Braak, 1991; Braak et al., 2006).”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Improved scoring of functional groups from gene expression data by decorrelating GO graph structure
Alexa, A., Rahnenführer, J., & Lengauer, T. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl140 · Cited by 2,188
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Cited by
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Alteration of the microRNA network during the progression of Alzheimer's disease
Lau, P., Bossers, K., Janky, R., Salta, E., Frigerio, C. S., Barbash, S., Rothman, R., Sierksma, A. S. R., Thathiah, A., Greenberg, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201974 · Cited by 474
Self-citationNeurodegenerative disease and adult neurogenesis
Winner, B., Kohl, Z., & Gage, F. H. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07613.x · Cited by 405
Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction
Orre, M., Kamphuis, W., Osborn, L. M., Jansen, A. H. P., Kooijman, L., Bossers, K., & Hol, E. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.004 · Cited by 394
Self-citationNeuroinflammation: Microglia and T Cells Get Ready to Tango
Schetters, S. T. T., Gomez-Nicola, D., Garcia-Vallejo, J. J., & Van Kooyk, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01905 · Cited by 382
Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study
Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., Iwaki, T., Ohara, T., Sasaki, T., LaFerla, F. M., et al. (2014) · Cerebral Cortex · doi:10.1093/cercor/bht101 · Cited by 322
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Adult Neurogenesis in Neurodegenerative Diseases: Figure 1.
Winner, B., & Winkler, J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021287 · Cited by 305
Yan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“…early pre-symptomatic stage, probably representing a coping mechanism against increased β -amyloid levels, and the decreased expression of these synaptic genes in later Braak stages, suggesting a reduction in synaptic activity that coincides with AD neuropathology and cognitive impairment [252].”
BackgroundXu, M., Zhang, D., Luo, R., Wu, Y., Zhou, H., Kong, L., Bi, R., & Yao, Y. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.012 · Cited by 296
Twine, N. A., Janitz, K., Wilkins, M. R., & Janitz, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016266 · Cited by 288
Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome
Hernández‐Ortega, K., Garcia‐Esparcia, P., Gil, L., Lucas, J. J., & Ferrer, I. (2016) · Brain Pathology · doi:10.1111/bpa.12335 · Cited by 245
“Several studies have shown altered gene expression in the postmortem brain of cases with AD and related animal models (7, 67, 99).”
BackgroundGene expression profiling in human neurodegenerative disease
Cooper-Knock, J., Kirby, J., Ferraiuolo, L., Heath, P. R., Rattray, M., & Shaw, P. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.156 · Cited by 223
Watson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., Haroutunian, V., & Sharp, A. J. (2016) · Genome Medicine · doi:10.1186/s13073-015-0258-8 · Cited by 201
“2b; Table 1) was recently shown to cleave and degrade β -amyloid (A β ) and mitigate A β -mediated toxicity in vitro [78], possibly consistent with the observed negative correlation between KLK7 expression and AD disease severity [79].”
β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease
Thathiah, A., Horré, K., Snellinx, A., Vandewyer, E., Huang, Y., Ciesielska, M., De Kloe, G., Munck, S., & De Strooper, B. (2013) · Nature Medicine · doi:10.1038/nm.3023 · Cited by 185
Luchetti, S., Huitinga, I., & Swaab, D. F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.010 · Cited by 176
Self-citationDiagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Soares Martins, T., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., da Cruz e Silva, O. A. B., & Henriques, A. G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 174
miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain
Salta, E., Sierksma, A., Vanden Eynden, E., & De Strooper, B. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606520 · Cited by 169
“…human prefrontal cortex, the normalized miRNA deep sequencing data were obtained from Lau et al (2013) and the normalized mRNA microarray data from Bossers et al (2010), both of which were performed on the prefrontal cortex of the same patient cohort from the Netherlands Brain Bank (Amsterdam,…”
BackgroundMethodInfluentialSkaper, S., Facci, L., & Giusti, P. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130224206 · Cited by 168
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156
Self-citationAbolhassani, N., Leon, J., Sheng, Z., Oka, S., Hamasaki, H., Iwaki, T., & Nakabeppu, Y. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.005 · Cited by 140
“neurological and immunological genes, genes encoding inflammatory molecules and metabolic enzymes (Bossers et al., 2010; Brooks et al., 2007; Colangelo et al., 2002; Hokama et al., 2014; Parachikova et al., 2007; Tan et al., 2010).”
BackgroundSynaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment
Counts, S. E., Alldred, M. J., Che, S., Ginsberg, S. D., & Mufson, E. J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.018 · Cited by 137
Ando, K., Brion, J.-P., Stygelbout, V., Suain, V., Authelet, M., Dedecker, R., Chanut, A., Lacor, P., Lavaur, J., Sazdovitch, V., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1111-z · Cited by 136
“Indeed, previous studies have reported that the expression level of PICALM mRNAs were either not significantly altered in AD prefrontal cortex [9] and in AD superior frontal gyrus [19, 78] or significantly increased in AD frontal cortex [4].”
BackgroundKazim, S. F., Seo, J. H., Bianchi, R., Larson, C. S., Sharma, A., Wong, R. K. S., Gorbachev, K., & Pereira, A. C. (2021) · eNeuro · doi:10.1523/eneuro.0418-20.2020 · Cited by 133
Parkinson's disease in the nuclear age of neuroinflammation
Nolan, Y. M., Sullivan, A. M., & Toulouse, A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.003 · Cited by 126
Berchtold, N. C., Sabbagh, M. N., Beach, T. G., Kim, R. C., Cribbs, D. H., & Cotman, C. W. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.031 · Cited by 124
Lesuis, S. L., Hoeijmakers, L., Korosi, A., de Rooij, S. R., Swaab, D. F., Kessels, H. W., Lucassen, P. J., & Krugers, H. J. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0422-7 · Cited by 115
Self-citationKazim, S. F., Chuang, S.-C., Zhao, W., Wong, R. K. S., Bianchi, R., & Iqbal, K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00071 · Cited by 109
“In human AD brains, intraneuronal Aβ accumulation also precedes plaque formation (Gyure et al., 2001; Bossers et al., 2010).”
BackgroundStargardt, A., Swaab, D. F., & Bossers, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.014 · Cited by 109
Self-citationQi, X., Kamphuis, W., Wang, S., Wang, Q., Lucassen, P. J., Zhou, J., & Swaab, D. F. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.09.014 · Cited by 109
Self-citationN-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution
Skaper, S. D., Facci, L., Barbierato, M., Zusso, M., Bruschetta, G., Impellizzeri, D., Cuzzocrea, S., & Giusti, P. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9253-8 · Cited by 108
Girard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., Marchetti, E., Khrestchatisky, M., Rivera, S., & Roman, F. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120982 · Cited by 107
Marquer, C., Laine, J., Dauphinot, L., Hanbouch, L., Lemercier-Neuillet, C., Pierrot, N., Bossers, K., Le, M., Corlier, F., Benstaali, C., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-60 · Cited by 103
Self-citationCrtc1 Activates a Transcriptional Program Deregulated at Early Alzheimer's Disease-Related Stages
Parra-Damas, A., Valero, J., Chen, M., España, J., Martín, E., Ferrer, I., Rodríguez-Alvarez, J., & Saura, C. A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5288-13.2014 · Cited by 101
Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases
Rydbirk, R., Folke, J., Winge, K., Aznar, S., Pakkenberg, B., & Brudek, T. (2016) · Scientific Reports · doi:10.1038/srep37116 · Cited by 100
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Guix, F. X., Sannerud, R., Berditchevski, F., Arranz, A. M., Horré, K., Snellinx, A., Thathiah, A., Saido, T., Saito, T., Rajesh, S., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0165-0 · Cited by 97
Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., Laplanche, J.-L., Meurs, E. F., Mouton-Liger, F., & Hugon, J. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140062 · Cited by 96
Concerted Perturbation Observed in a Hub Network in Alzheimer’s Disease
Liang, D., Han, G., Feng, X., Sun, J., Duan, Y., & Lei, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040498 · Cited by 93
“significantly in later stages [116].”
Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease
Rossi, B., Santos-Lima, B., Terrabuio, E., Zenaro, E., & Constantin, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639369 · Cited by 92
Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases
Li, M. D., Burns, T. C., Morgan, A. A., & Khatri, P. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0093-y · Cited by 92
Aggregates of Small Nuclear Ribonucleic Acids ( snRNAs ) in Alzheimer's Disease
Hales, C. M., Dammer, E. B., Diner, I., Yi, H., Seyfried, N. T., Gearing, M., Glass, J. D., Montine, T. J., Levey, A. I., & Lah, J. J. (2014) · Brain Pathology · doi:10.1111/bpa.12133 · Cited by 89
“We therefore immunostained frontal cortex from available CBD and FTD-tau cases (Supporting Information Table S1) with the 2,2,7-TMG cap monoclonal antibody.”
BackgroundInfluentialEvidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment
Weinberg, R. B., Mufson, E. J., & Counts, S. E. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00430 · Cited by 88
Huang, Y., Skwarek-Maruszewska, A., Horré, K., Vandewyer, E., Wolfs, L., Snellinx, A., Saito, T., Radaelli, E., Corthout, N., Colombelli, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3492 · Cited by 88
Self-citationVisser, P. J., Reus, L. M., Gobom, J., Jansen, I., Dicks, E., van der Lee, S. J., Tsolaki, M., Verhey, F. R. J., Popp, J., Martinez-Lage, P., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00521-3 · Cited by 87
Desplats, P., Gutierrez, A. M., Antonelli, M. C., & Frasch, M. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.013 · Cited by 86
Amyloid-β Oligomers Induce Differential Gene Expression in Adult Human Brain Slices
Sebollela, A., Freitas-Correa, L., Oliveira, F. F., Paula-Lima, A. C., Saraiva, L. M., Martins, S. M., Mota, L. D., Torres, C., Alves-Leon, S., de Souza, J. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.298471 · Cited by 85
Zhu, Q.-B., Unmehopa, U., Bossers, K., Hu, Y.-T., Verwer, R., Balesar, R., Zhao, J., Bao, A.-M., & Swaab, D. (2016) · Brain · doi:10.1093/brain/awv383 · Cited by 85
Self-citationAlterations in the histaminergic system in Alzheimer's disease: a postmortem study
Shan, L., Bossers, K., Unmehopa, U., Bao, A.-M., & Swaab, D. F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.026 · Cited by 84
Self-citationLeandro, G. D. S., Evangelista, A. F., Lôbo, R. R., Xavier, D. J., Moriguti, J. C., & Sakamoto‐Hojo, E. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170205 · Cited by 81
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 80
β-Arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology
Liu, X., Zhao, X., Zeng, X., Bossers, K., Swaab, D. F., Zhao, J., & Pei, G. (2013) · Cell Research · doi:10.1038/cr.2012.167 · Cited by 80
Self-citationDysfunction of the mTOR pathway is a risk factor for Alzheimer's disease
Yates, S. C., Zafar, A., Hubbard, P., Nagy, S., Durant, S., Bicknell, R., Wilcock, G., Christie, S., Esiri, M. M., Smith, A. D., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-3 · Cited by 76
“The molecular pathways and functions we have found affected in AD are largely the same as those identified earlier in brain regions severely affected by the disease [40,42-45] or those found to be altered in parallel with increased beta amyloid load in the brain [46], with the significant difference that we have now p…”
BackgroundBouter, Y., Kacprowski, T., Weissmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00075 · Cited by 76
Abnormal Retinoid and TrkB Signaling in the Prefrontal Cortex in Mood Disorders
Qi, X.-R., Zhao, J., Liu, J., Fang, H., Swaab, D. F., & Zhou, J.-N. (2015) · Cerebral Cortex · doi:10.1093/cercor/bht203 · Cited by 76
Self-citationGenome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration
Koldamova, R., Schug, J., Lefterova, M., Cronican, A. A., Fitz, N. F., Davenport, F. A., Carter, A., Castranio, E. L., & Lefterov, I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.005 · Cited by 75
Kee, T. R., Khan, S. A., Neidhart, M. B., Masters, B. M., Zhao, V. K., Kim, Y. K., Percy, K. C. M., & Woo, J. A. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01144-4 · Cited by 75
de Vries, L. E., Huitinga, I., Kessels, H. W., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 72
Self-citationE. Hirbec, H., Noristani, H. N., & Perrin, F. E. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00227 · Cited by 71
Zhao, J., Bao, A.-M., Qi, X.-R., Kamphuis, W., Luchetti, S., Lou, J.-S., & Swaab, D. F. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.013 · Cited by 70
Self-citationMendonça, C. F., Kuras, M., Nogueira, F. C. S., Plá, I., Hortobágyi, T., Csiba, L., Palkovits, M., Renner, É., Döme, P., Marko-Varga, G., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104509 · Cited by 70
Tuning GABAergic Inhibition: Gephyrin Molecular Organization and Functions
Pizzarelli, R., Griguoli, M., Zacchi, P., Petrini, E. M., Barberis, A., Cattaneo, A., & Cherubini, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.07.036 · Cited by 69
“This is in accordance with the increased activation of genes encoding for synaptic proteins, including those involved in inhibitory synapses organization, observed in AD patients before the onset of cognitive deficits (Bossers et al., 2010).”
Metallothionein and brain inflammation
Manso, Y., Adlard, P. A., Carrasco, J., Vašák, M., & Hidalgo, J. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0802-y · Cited by 69
Ellison, E. M., Abner, E. L., & Lovell, M. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13912 · Cited by 68
Stargardt, A., Gillis, J., Kamphuis, W., Wiemhoefer, A., Kooijman, L., Raspe, M., Benckhuijsen, W., Drijfhout, J. W., M. Hol, E., & Reits, E. (2013) · Aging Cell · doi:10.1111/acel.12074 · Cited by 67
Multispectral Imaging: A Review of Its Technical Aspects and Applications in Anatomic Pathology
Mansfield, J. R. (2013) · Veterinary Pathology · doi:10.1177/0300985813506918 · Cited by 67
Ianov, L., Riva, A., Kumar, A., & Foster, T. C. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00249 · Cited by 66
Wirz, K. T. S., Bossers, K., Stargardt, A., Kamphuis, W., Swaab, D. F., Hol, E. M., & Verhaagen, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.008 · Cited by 65
Self-citationCarlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V. A., Kitchen, R. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.012 · Cited by 65
Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
Saura, C. A., Parra-Damas, A., & Enriquez-Barreto, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00318 · Cited by 65
Calió, M. L., Henriques, E., Siena, A., Bertoncini, C. R. A., Gil-Mohapel, J., & Rosenstock, T. R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00679 · Cited by 64
Genes associated with the progression of neurofibrillary tangles in Alzheimer’s disease
Miyashita, A., Hatsuta, H., Kikuchi, M., Nakaya, A., Saito, Y., Tsukie, T., Hara, N., Ogishima, S., Kitamura, N., Akazawa, K., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.35 · Cited by 64
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Ortiz-Sanz, C., Balantzategi, U., Quintela‐López, T., Ruiz, A., Luchena, C., Zuazo-Ibarra, J., Capetillo‐Zarate, E., Matute, C., Zugaza, J. L., & Alberdi, E. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04687-y · Cited by 63
Revealing cell vulnerability in Alzheimer’s disease by single-cell transcriptomics
Saura, C. A., Deprada-Fernandez, Á., Capilla-López, M. D., & Parra‐Damas, A. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.05.007 · Cited by 61
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 61
Kidana, K., Tatebe, T., Ito, K., Hara, N., Kakita, A., Saito, T., Takatori, S., Ouchi, Y., Ikeuchi, T., Makino, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708184 · Cited by 61
Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer’s Disease
Mahady, L., Nadeem, M., Malek-Ahmadi, M., Chen, K., Perez, S. E., & Mufson, E. J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171032 · Cited by 61
Neurodegeneration as an RNA disorder
Johnson, R., Noble, W. J., Tartaglia, G. G., & Buckley, N. J. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.09.006 · Cited by 61
Galán, L., Gómez-Pinedo, U., Guerrero, A., García-Verdugo, J. M., & Matías-Guiu, J. (2017) · BMC Neurology · doi:10.1186/s12883-017-0956-5 · Cited by 60
Decreased NOS1 Expression in the Anterior Cingulate Cortex in Depression
Gao, S.-F., Qi, X.-R., Zhao, J., Balesar, R., Bao, A.-M., & Swaab, D. F. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs285 · Cited by 59
Self-citationHales, C. M., Seyfried, N. T., Dammer, E. B., Duong, D., Yi, H., Gearing, M., Troncoso, J. C., Mufson, E. J., Thambisetty, M., Levey, A. I., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-15 · Cited by 58
“Changes in alternative splicing have been associated with neurodegeneration [7] including AD [8,9].”
Alzheimer Amyloid Peptide Aβ42 Regulates Gene Expression of Transcription and Growth Factors
Barucker, C., Sommer, A., Beckmann, G., Eravci, M., Harmeier, A., Schipke, C. G., Brockschnieder, D., Dyrks, T., Althoff, V., Fraser, P. E., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141902 · Cited by 58
A novel peptidomics approach to detect markers of Alzheimer’s disease in cerebrospinal fluid
Wijte, D., McDonnell, L. A., Balog, C. I. A., Bossers, K., Deelder, A. M., Swaab, D. F., Verhaagen, J., & Mayboroda, O. A. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.018 · Cited by 57
Self-citationSilva, P. N., Furuya, T. K., Braga, I. L., Rasmussen, L. T., Labio, R. W., Bertolucci, P. H., Chen, E. S., Turecki, G., Mechawar, N., Payão, S. L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130428 · Cited by 55
Martins‐de‐Souza, D., Guest, P. C., Mann, D. M. A., Roeber, S., Rahmoune, H., Bauder, C. A., Kretzschmar, H. A., Volk, B., Baborie, A., & Bahn, S. (2012) · Journal of Proteome Research · doi:10.1021/pr2012279 · Cited by 55
Age and Sex Influence the Hippocampal Response and Recovery Following Sepsis
Barter, J., Kumar, A., Stortz, J. A., Hollen, M. K., Nacionales, D. C., Efron, P. A., Moldawer, L. L., & Foster, T. C. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01681-y · Cited by 55
Hixson, K. M., Cogswell, M., Brooks‐Kayal, A. R., & Russek, S. J. (2019) · BMC Genomics · doi:10.1186/s12864-019-6033-2 · Cited by 55
A multiomic approach to characterize the temporal sequence in Alzheimer's disease-related pathology
Marttinen, M., Paananen, J., Neme, A., Mitra, V., Takalo, M., Natunen, T., Paldanius, K. M. A., Mäkinen, P., Bremang, M., Kurki, M. I., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.009 · Cited by 54
Buchanan, H., Mackay, M., Palmer, K., Tothová, K., Katsur, M., Platt, B., & Koss, D. J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01950-1 · Cited by 54
Borjabad, A., & Volsky, D. J. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9409-5 · Cited by 51
New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease
Medina, M., & Avila, J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.843670 · Cited by 50
Caberlotto, L., Lauria, M., Nguyen, T.-P., & Scotti, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078919 · Cited by 49
Sun, J., Feng, X., Liang, D., Duan, Y., & Lei, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111313 · Cited by 49
Hu, Y., Chen, X., Huang, S., Zhu, Q., Yu, S., Shen, Y. L., Sluiter, A. A., Verhaagen, J., Zhao, J., Swaab, D. F., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12688 · Cited by 47
Self-citationCell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease
Wang, X.-L., & Li, L. (2021) · BMC Neurology · doi:10.1186/s12883-021-02407-1 · Cited by 46
Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?
Wirz, K. T. S., Keitel, S., Swaab, D. F., Verhaagen, J., & Bossers, K. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130920 · Cited by 46
Self-citationSynapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 46
Metadata
- Authors
- Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F.
- Affiliations
- Netherlands Institute for Neuroscience (NL)
- Abbott (Netherlands) (NL)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-01
- Volume
- 133
- Issue
- 12
- Pages
- 3699-3723
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2084210522
- Cited by
- 230
- References
- 93
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 12 · 2019: 15 · 2018: 13 · 2017: 16 · 2016: 13 · 2015: 16 · 2014: 17 · 2013: 23 · 2012: 18
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Top Institute Pharma (T5-207)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- prefrontal cortex, gene expression changes, Braak staging, neurofibrillary tangles, amyloid plaques, amyloid-beta, synaptic activity, synaptic plasticity, APOE ε4, APP processing, mild cognitive impairment, presymptomatic stage
- MeSH terms
- Aged, Aging, Alzheimer Disease, Apolipoproteins E, Female, Multigene Family, Humans, Immunohistochemistry, Male, Synaptic Transmission, Nucleic Acid Hybridization, RNA, Transcription, Genetic, Blotting, Western, Gene Expression, Amyloid beta-Peptides, Prefrontal Cortex, Disease Progression, Reverse Transcriptase Polymerase Chain Reaction, Sirtuins, Microarray Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.